ViroPharma Incorporated (VPHM)

[surf1944]

7:38AM ViroPharma reports Q4 (Dec) results, beats on revs (VPHM) 10.55 : Reports Q4 (Dec) earnings of $0.15 per share, may not be comparable to the First Call consensus of $0.24; revenues rose 75.6% year/year to $87.8 mln vs the $82.5 mln consensus. Co increases 2010 Net Cinryze sales of $150 to $175 million. Global selling, general and administrative (SG&A) and research and development (R&D) expenses, including the impact of SFAS 123R, are expected to be $125 to $140 million. SFAS 123R expenses are expected to be between $10 and $12 million.